Renaissance Technologies (RenTech)'s CORT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 5.76 M shares of Corcept Therapeutics Incorporated (CORT) worth $200.4 M, representing 0.31% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in CORT, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2017, adding 1.28 M shares. Largest reduction occurred in Q3 2022, reducing 636,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Corcept Therapeutics Incorporated (CORT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corcept Therapeutics Incorporated (CORT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -330,819 | Reduce 5.43% | 5.76 M | $34.80 |
| Q3 2025 | -177,055 | Reduce 2.83% | 6.09 M | $83.11 |
| Q2 2025 | +123,371 | Add 2.01% | 6.27 M | $73.40 |
| Q1 2025 | -55,571 | Reduce 0.90% | 6.14 M | $114.22 |
| Q4 2024 | -310,400 | Reduce 4.77% | 6.2 M | $50.39 |
| Q3 2024 | -403,569 | Reduce 5.84% | 6.51 M | $46.28 |
| Q2 2024 | -205,800 | Reduce 2.89% | 6.91 M | $32.49 |
| Q1 2024 | +392,500 | Add 5.84% | 7.12 M | $25.19 |
| Q4 2023 | +111,000 | Add 1.68% | 6.73 M | $32.48 |
| Q3 2023 | -85,100 | Reduce 1.27% | 6.61 M | $27.24 |
| Q2 2023 | -88,098 | Reduce 1.30% | 6.7 M | $0.02 |
| Q1 2023 | -500,802 | Reduce 6.87% | 6.79 M | $0.02 |
| Q4 2022 | +91,400 | Add 1.27% | 7.29 M | $0.02 |
| Q3 2022 | -636,400 | Reduce 8.12% | 7.2 M | $25.64 |
| Q2 2022 | +63,355 | Add 0.82% | 7.83 M | $23.78 |
| Q1 2022 | -253,100 | Reduce 3.15% | 7.77 M | $22.52 |
| Q4 2021 | -224,225 | Reduce 2.72% | 8.02 M | $19.80 |
| Q3 2021 | -274,355 | Reduce 3.22% | 8.25 M | $19.68 |
| Q2 2021 | -251,600 | Reduce 2.87% | 8.52 M | $22.00 |
| Q1 2021 | -567,700 | Reduce 6.08% | 8.77 M | $23.79 |
| Q4 2020 | -264,500 | Reduce 2.75% | 9.34 M | $26.16 |
| Q3 2020 | +686,000 | Add 7.69% | 9.61 M | $17.40 |
| Q2 2020 | +617,155 | Add 7.43% | 8.92 M | $16.82 |
| Q1 2020 | +534,627 | Add 6.88% | 8.3 M | $11.89 |
| Q4 2019 | +1.24 M | Add 19.07% | 7.77 M | $12.10 |
| Q3 2019 | +933,700 | Add 16.70% | 6.52 M | $14.14 |
| Q2 2019 | +532,700 | Add 10.53% | 5.59 M | $11.15 |
| Q1 2019 | +410,600 | Add 8.84% | 5.06 M | $11.74 |
| Q4 2018 | +231,609 | Add 5.25% | 4.65 M | $13.36 |
| Q3 2018 | +70,200 | Add 1.62% | 4.42 M | $14.02 |
| Q2 2018 | -453,100 | Reduce 9.44% | 4.35 M | $15.72 |
| Q1 2018 | -156,000 | Reduce 3.15% | 4.8 M | $16.45 |
| Q4 2017 | +1.28 M | Add 35.01% | 4.95 M | $18.06 |
| Q3 2017 | +986,355 | Add 36.76% | 3.67 M | $19.30 |
| Q2 2017 | +824,900 | Add 44.39% | 2.68 M | $11.80 |
| Q1 2017 | +351,000 | Add 23.28% | 1.86 M | $10.96 |
| Q4 2016 | +947,500 | Add 169.20% | 1.51 M | $7.26 |
| Q3 2016 | +249,400 | Add 80.30% | 560,000 | $6.50 |
| Q2 2016 | +119,200 | Add 62.28% | 310,600 | $5.46 |
| Q1 2016 | -269,000 | Reduce 58.43% | 191,400 | $4.68 |
| Q4 2015 | +8,200 | Add 1.81% | 460,400 | $4.98 |
| Q3 2015 | -49,414 | Reduce 9.85% | 452,200 | $3.76 |
| Q2 2015 | +446,214 | Add 805.44% | 501,614 | $6.01 |
| Q1 2015 | +55,400 | New Buy | 55,400 | $5.60 |
Renaissance Technologies (RenTech)'s Corcept Therapeutics Incorporated Investment FAQs
Renaissance Technologies (RenTech) first purchased Corcept Therapeutics Incorporated (CORT) in Q1 2015, acquiring 55,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Corcept Therapeutics Incorporated (CORT) for 44 quarters since Q1 2015.
Renaissance Technologies (RenTech)'s largest addition to Corcept Therapeutics Incorporated (CORT) was in Q4 2017, adding 4,954,500 shares worth $89.48 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 5,758,528 shares of Corcept Therapeutics Incorporated (CORT), valued at approximately $200.4 M.
As of the Q4 2025 filing, Corcept Therapeutics Incorporated (CORT) represents approximately 0.31% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Corcept Therapeutics Incorporated (CORT) was 9,605,996 shares, as reported at the end of Q3 2020.